Further, anti-HER2 therapy coupled with PD-1 therapy is an established, safe treatment combination used for GI malignancies, and it is standard of care for first-line therapy of advanced HER2+ gastric cancer per the results of Keynote 8116. The gene discussed is ERBB2; the disease is gastric cancer.